Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 17 entries
Sorted by: Best Match Show Resources per page
From the Biology of PP2A to the PADs for Therapy of Hematologic Malignancies.

Frontiers in oncology

Ciccone M, Calin GA, Perrotti D.
PMID: 25763353
Front Oncol. 2015 Feb 16;5:21. doi: 10.3389/fonc.2015.00021. eCollection 2015.

Over the past decades, an emerging role of phosphatases in the pathogenesis of hematologic malignancies and solid tumors has been established. The tumor-suppressor protein phosphatase 2A (PP2A) belongs to the serine-threonine phosphatases family and accounts for the majority of...

Cite
Ciccone M, Calin GA, Perrotti D. From the Biology of PP2A to the PADs for Therapy of Hematologic Malignancies. Front Oncol. 2015;5:21doi: 10.3389/fonc.2015.00021.
Ciccone, M., Calin, G. A., & Perrotti, D. (2015). From the Biology of PP2A to the PADs for Therapy of Hematologic Malignancies. Frontiers in oncology, 521. https://doi.org/10.3389/fonc.2015.00021
Ciccone, Maria, et al. "From the Biology of PP2A to the PADs for Therapy of Hematologic Malignancies." Frontiers in oncology vol. 5 (2015): 21. doi: https://doi.org/10.3389/fonc.2015.00021
Ciccone M, Calin GA, Perrotti D. From the Biology of PP2A to the PADs for Therapy of Hematologic Malignancies. Front Oncol. 2015 Feb 16;5:21. doi: 10.3389/fonc.2015.00021. eCollection 2015. PMID: 25763353; PMCID: PMC4329809.
Copy Download .nbib Format: NLM
An updated h-index measures both the primary and total scientific output of a researcher.

Discoveries (Craiova, Romania)

Bucur O, Almasan A, Zubarev R, Friedman M, Nicolson GL, Sumazin P, Leabu M, Nikolajczyk BS, Avram D, Kunej T, Calin GA, Godwin AK, Adami HO, Zaphiropoulos PG, Richardson DR, Schmitt-Ulms G, Westerblad H, Keniry M, Grau GE, Carbonetto S, Stan RV, Popa-Wagner A, Takhar K, Baron BW, Galardy PJ, Yang F, Data D, Fadare O, Yeo KJ, Gabreanu GR, Andrei S, Soare GR, Nelson MA, Liehn EA.
PMID: 26504901
Discoveries (Craiova). 2015 Jul-Sep;3(3). doi: 10.15190/d.2015.42. Epub 2015 Sep 30.

The growing interest in scientometry stems from ethical concerns related to the proper evaluation of scientific contributions of an author working in a hard science. In the absence of a consensus, institutions may use arbitrary methods for evaluating scientists...

Cite
Bucur O, Almasan A, Zubarev R, et al. An updated h-index measures both the primary and total scientific output of a researcher. Discoveries (Craiova). 2015;3(3)doi: 10.15190/d.2015.42.
Bucur, O., Almasan, A., Zubarev, R., Friedman, M., Nicolson, G. L., Sumazin, P., Leabu, M., Nikolajczyk, B. S., Avram, D., Kunej, T., Calin, G. A., Godwin, A. K., Adami, H. O., Zaphiropoulos, P. G., Richardson, D. R., Schmitt-Ulms, G., Westerblad, H., Keniry, M., Grau, G. E., Carbonetto, S., Stan, R. V., Popa-Wagner, A., Takhar, K., Baron, B. W., Galardy, P. J., Yang, F., Data, D., Fadare, O., Yeo, K. J., Gabreanu, G. R., Andrei, S., Soare, G. R., Nelson, M. A., & Liehn, E. A. (2015). An updated h-index measures both the primary and total scientific output of a researcher. Discoveries (Craiova, Romania), 3(3), . https://doi.org/10.15190/d.2015.42
Bucur, Octavian, et al. "An updated h-index measures both the primary and total scientific output of a researcher." Discoveries (Craiova, Romania) vol. 3,3 (2015). doi: https://doi.org/10.15190/d.2015.42
Bucur O, Almasan A, Zubarev R, Friedman M, Nicolson GL, Sumazin P, Leabu M, Nikolajczyk BS, Avram D, Kunej T, Calin GA, Godwin AK, Adami HO, Zaphiropoulos PG, Richardson DR, Schmitt-Ulms G, Westerblad H, Keniry M, Grau GE, Carbonetto S, Stan RV, Popa-Wagner A, Takhar K, Baron BW, Galardy PJ, Yang F, Data D, Fadare O, Yeo KJ, Gabreanu GR, Andrei S, Soare GR, Nelson MA, Liehn EA. An updated h-index measures both the primary and total scientific output of a researcher. Discoveries (Craiova). 2015 Jul-Sep;3(3). doi: 10.15190/d.2015.42. Epub 2015 Sep 30. PMID: 26504901; PMCID: PMC4617786.
Copy Download .nbib Format: NLM
MicroRNAs from Liquid Biopsy Derived Extracellular Vesicles: Recent Advances in Detection and Characterization Methods.

Cancers

Drula R, Ott LF, Berindan-Neagoe I, Pantel K, Calin GA.
PMID: 32707943
Cancers (Basel). 2020 Jul 22;12(8). doi: 10.3390/cancers12082009.

Liquid biopsies have become a convenient tool in cancer diagnostics, real-time disease monitoring, and evaluation of residual disease. Yet, the information still encrypted in the variety of tumor-derived molecules identified in biofluids has proven difficult to decipher due to...

Cite
Drula R, Ott LF, Berindan-Neagoe I, et al. MicroRNAs from Liquid Biopsy Derived Extracellular Vesicles: Recent Advances in Detection and Characterization Methods. Cancers (Basel). 2020;12(8)doi: 10.3390/cancers12082009.
Drula, R., Ott, L. F., Berindan-Neagoe, I., Pantel, K., & Calin, G. A. (2020). MicroRNAs from Liquid Biopsy Derived Extracellular Vesicles: Recent Advances in Detection and Characterization Methods. Cancers, 12(8), . https://doi.org/10.3390/cancers12082009
Drula, Rares, et al. "MicroRNAs from Liquid Biopsy Derived Extracellular Vesicles: Recent Advances in Detection and Characterization Methods." Cancers vol. 12,8 (2020). doi: https://doi.org/10.3390/cancers12082009
Drula R, Ott LF, Berindan-Neagoe I, Pantel K, Calin GA. MicroRNAs from Liquid Biopsy Derived Extracellular Vesicles: Recent Advances in Detection and Characterization Methods. Cancers (Basel). 2020 Jul 22;12(8). doi: 10.3390/cancers12082009. PMID: 32707943; PMCID: PMC7465219.
Copy Download .nbib Format: NLM
ncRNA therapy with miRNA-22-3p suppresses the growth of triple-negative breast cancer.

Molecular therapy. Nucleic acids

Gorur A, Bayraktar R, Ivan C, Mokhlis HA, Bayraktar E, Kahraman N, Karakas D, Karamil S, Kabil NN, Kanlikilicer P, Aslan B, Tamer L, Wang Z, Cristini V, Lopez-Berestein G, Calin G, Ozpolat B.
PMID: 33614241
Mol Ther Nucleic Acids. 2021 Jan 20;23:930-943. doi: 10.1016/j.omtn.2021.01.016. eCollection 2021 Mar 05.

Deregulation of noncoding RNAs, including microRNAs (miRs), is implicated in the pathogenesis of many human cancers, including breast cancer. Through extensive analysis of The Cancer Genome Atlas, we found that expression of miR-22-3p is markedly lower in triple-negative breast...

Cite
Gorur A, Bayraktar R, Ivan C, et al. ncRNA therapy with miRNA-22-3p suppresses the growth of triple-negative breast cancer. Mol Ther Nucleic Acids. 2021;23:930-943doi: 10.1016/j.omtn.2021.01.016.
Gorur, A., Bayraktar, R., Ivan, C., Mokhlis, H. A., Bayraktar, E., Kahraman, N., Karakas, D., Karamil, S., Kabil, N. N., Kanlikilicer, P., Aslan, B., Tamer, L., Wang, Z., Cristini, V., Lopez-Berestein, G., Calin, G., & Ozpolat, B. (2021). ncRNA therapy with miRNA-22-3p suppresses the growth of triple-negative breast cancer. Molecular therapy. Nucleic acids, 23930-943. https://doi.org/10.1016/j.omtn.2021.01.016
Gorur, Aysegul, et al. "ncRNA therapy with miRNA-22-3p suppresses the growth of triple-negative breast cancer." Molecular therapy. Nucleic acids vol. 23 (2021): 930-943. doi: https://doi.org/10.1016/j.omtn.2021.01.016
Gorur A, Bayraktar R, Ivan C, Mokhlis HA, Bayraktar E, Kahraman N, Karakas D, Karamil S, Kabil NN, Kanlikilicer P, Aslan B, Tamer L, Wang Z, Cristini V, Lopez-Berestein G, Calin G, Ozpolat B. ncRNA therapy with miRNA-22-3p suppresses the growth of triple-negative breast cancer. Mol Ther Nucleic Acids. 2021 Jan 20;23:930-943. doi: 10.1016/j.omtn.2021.01.016. eCollection 2021 Mar 05. PMID: 33614241; PMCID: PMC7868999.
Copy Download .nbib Format: NLM
The role of exosomal long non-coding RNAs in cancer drug resistance.

Cancer drug resistance (Alhambra, Calif.)

De Los Santos MC, Dragomir MP, Calin GA.
PMID: 31867576
Cancer Drug Resist. 2019 Dec 19;2:1178-1192. doi: 10.20517/cdr.2019.74.

One of the major challenges in oncology is drug resistance, which triggers relapse and shortens patients' survival. In order to promote drug desensitization, cancer cells require the establishment of an ideal tumor microenvironment that accomplishes specific conditions. To achieve...

Cite
De Los Santos MC, Dragomir MP, Calin GA. The role of exosomal long non-coding RNAs in cancer drug resistance. Cancer Drug Resist. 2019;2:1178-1192doi: 10.20517/cdr.2019.74.
De Los Santos, M. C., Dragomir, M. P., & Calin, G. A. (2019). The role of exosomal long non-coding RNAs in cancer drug resistance. Cancer drug resistance (Alhambra, Calif.), 21178-1192. https://doi.org/10.20517/cdr.2019.74
De Los Santos, Mireia Cruz, et al. "The role of exosomal long non-coding RNAs in cancer drug resistance." Cancer drug resistance (Alhambra, Calif.) vol. 2 (2019): 1178-1192. doi: https://doi.org/10.20517/cdr.2019.74
De Los Santos MC, Dragomir MP, Calin GA. The role of exosomal long non-coding RNAs in cancer drug resistance. Cancer Drug Resist. 2019 Dec 19;2:1178-1192. doi: 10.20517/cdr.2019.74. PMID: 31867576; PMCID: PMC6924635.
Copy Download .nbib Format: NLM
MicroRNAs in Myeloid Hematological Malignancies.

Current genomics

Ciccone M, Calin GA.
PMID: 27047254
Curr Genomics. 2015 Oct;16(5):336-48. doi: 10.2174/138920291605150710122815.

MicroRNAs are 19-24 nucleotides noncoding RNAs which silence modulate the expression of target genes by binding to the messenger RNAs. Myeloid malignancies include a broad spectrum of acute and chronic disorders originating from from the clonal transformation of a...

Cite
Ciccone M, Calin GA. MicroRNAs in Myeloid Hematological Malignancies. Curr Genomics. 2015;16(5):336-48doi: 10.2174/138920291605150710122815.
Ciccone, M., & Calin, G. A. (2015). MicroRNAs in Myeloid Hematological Malignancies. Current genomics, 16(5), 336-48. https://doi.org/10.2174/138920291605150710122815
Ciccone, Maria, and Calin, George Adrian. "MicroRNAs in Myeloid Hematological Malignancies." Current genomics vol. 16,5 (2015): 336-48. doi: https://doi.org/10.2174/138920291605150710122815
Ciccone M, Calin GA. MicroRNAs in Myeloid Hematological Malignancies. Curr Genomics. 2015 Oct;16(5):336-48. doi: 10.2174/138920291605150710122815. PMID: 27047254; PMCID: PMC4763972.
Copy Download .nbib Format: NLM
A unique microRNA profile in end-stage heart failure indicates alterations in specific cardiovascular signaling networks.

The Journal of biological chemistry

[No authors listed]
PMID: 27422978
J Biol Chem. 2016 Jul 15;291(29):14914. doi: 10.1074/jbc.A109.036541.

No abstract available.

Cite
A unique microRNA profile in end-stage heart failure indicates alterations in specific cardiovascular signaling networks. J Biol Chem. 2016;291(29):14914doi: 10.1074/jbc.A109.036541.
(2016). A unique microRNA profile in end-stage heart failure indicates alterations in specific cardiovascular signaling networks. The Journal of biological chemistry, 291(29), 14914. https://doi.org/10.1074/jbc.A109.036541
"A unique microRNA profile in end-stage heart failure indicates alterations in specific cardiovascular signaling networks." The Journal of biological chemistry vol. 291,29 (2016): 14914. doi: https://doi.org/10.1074/jbc.A109.036541
A unique microRNA profile in end-stage heart failure indicates alterations in specific cardiovascular signaling networks. J Biol Chem. 2016 Jul 15;291(29):14914. doi: 10.1074/jbc.A109.036541. PMID: 27422978; PMCID: PMC4946910.
Copy Download .nbib Format: NLM
Key principles of miRNA involvement in human diseases.

Discoveries (Craiova, Romania)

Giza DE, Vasilescu C, Calin GA.
PMID: 26317116
Discoveries (Craiova). 2014 Oct-Dec;2(4):e34. doi: 10.15190/d.2014.26.

Although rapid progress in our understanding of the functions of miRNA has been made by experimentation and computational approach, a considerable effort still has to be done in determining the general principles that govern the miRNA's mode of action...

Cite
Giza DE, Vasilescu C, Calin GA. Key principles of miRNA involvement in human diseases. Discoveries (Craiova). 2014;2(4):e34doi: 10.15190/d.2014.26.
Giza, D. E., Vasilescu, C., & Calin, G. A. (2014). Key principles of miRNA involvement in human diseases. Discoveries (Craiova, Romania), 2(4), e34. https://doi.org/10.15190/d.2014.26
Giza, Dana Elena, et al. "Key principles of miRNA involvement in human diseases." Discoveries (Craiova, Romania) vol. 2,4 (2014): e34. doi: https://doi.org/10.15190/d.2014.26
Giza DE, Vasilescu C, Calin GA. Key principles of miRNA involvement in human diseases. Discoveries (Craiova). 2014 Oct-Dec;2(4):e34. doi: 10.15190/d.2014.26. PMID: 26317116; PMCID: PMC4547364.
Copy Download .nbib Format: NLM
MicroRNA Processing and Human Cancer.

Journal of clinical medicine

Ohtsuka M, Ling H, Doki Y, Mori M, Calin GA.
PMID: 26308063
J Clin Med. 2015 Aug 21;4(8):1651-67. doi: 10.3390/jcm4081651.

MicroRNAs (miRNAs) are short non-coding RNAs of 20 to 25 nucleotides that regulate gene expression post-transcriptionally mainly by binding to a specific sequence of the 3' end of the untranslated region (3'UTR) of target genes. Since the first report...

Cite
Ohtsuka M, Ling H, Doki Y, et al. MicroRNA Processing and Human Cancer. J Clin Med. 2015;4(8):1651-67doi: 10.3390/jcm4081651.
Ohtsuka, M., Ling, H., Doki, Y., Mori, M., & Calin, G. A. (2015). MicroRNA Processing and Human Cancer. Journal of clinical medicine, 4(8), 1651-67. https://doi.org/10.3390/jcm4081651
Ohtsuka, Masahisa, et al. "MicroRNA Processing and Human Cancer." Journal of clinical medicine vol. 4,8 (2015): 1651-67. doi: https://doi.org/10.3390/jcm4081651
Ohtsuka M, Ling H, Doki Y, Mori M, Calin GA. MicroRNA Processing and Human Cancer. J Clin Med. 2015 Aug 21;4(8):1651-67. doi: 10.3390/jcm4081651. PMID: 26308063; PMCID: PMC4555082.
Copy Download .nbib Format: NLM
Gut microbiota: a new player in regulating immune- and chemo-therapy efficacy.

Cancer drug resistance (Alhambra, Calif.)

Anfossi S, Calin GA.
PMID: 33062956
Cancer Drug Resist. 2020;3:356-370. doi: 10.20517/cdr.2020.04. Epub 2020 Mar 21.

Development of drug resistance represents the major cause of cancer therapy failure, determines disease progression and results in poor prognosis for cancer patients. Different mechanisms are responsible for drug resistance. Intrinsic genetic modifications of cancer cells induce the alteration...

Cite
Anfossi S, Calin GA. Gut microbiota: a new player in regulating immune- and chemo-therapy efficacy. Cancer Drug Resist. 2020;3:356-370doi: 10.20517/cdr.2020.04.
Anfossi, S., & Calin, G. A. (2020). Gut microbiota: a new player in regulating immune- and chemo-therapy efficacy. Cancer drug resistance (Alhambra, Calif.), 3356-370. https://doi.org/10.20517/cdr.2020.04
Anfossi, Simone, and Calin, George A. "Gut microbiota: a new player in regulating immune- and chemo-therapy efficacy." Cancer drug resistance (Alhambra, Calif.) vol. 3 (2020): 356-370. doi: https://doi.org/10.20517/cdr.2020.04
Anfossi S, Calin GA. Gut microbiota: a new player in regulating immune- and chemo-therapy efficacy. Cancer Drug Resist. 2020;3:356-370. doi: 10.20517/cdr.2020.04. Epub 2020 Mar 21. PMID: 33062956; PMCID: PMC7556722.
Copy Download .nbib Format: NLM
Decomposing the Apoptosis Pathway Into Biologically Interpretable Principal Components.

Cancer informatics

Wang M, Kornblau SM, Coombes KR.
PMID: 29881252
Cancer Inform. 2018 May 09;17:1176935118771082. doi: 10.1177/1176935118771082. eCollection 2018.

Principal component analysis (PCA) is one of the most common techniques in the analysis of biological data sets, but applying PCA raises 2 challenges. First, one must determine the number of significant principal components (PCs). Second, because each PC...

Cite
Wang M, Kornblau SM, Coombes KR. Decomposing the Apoptosis Pathway Into Biologically Interpretable Principal Components. Cancer Inform. 2018;17:1176935118771082doi: 10.1177/1176935118771082.
Wang, M., Kornblau, S. M., & Coombes, K. R. (2018). Decomposing the Apoptosis Pathway Into Biologically Interpretable Principal Components. Cancer informatics, 171176935118771082. https://doi.org/10.1177/1176935118771082
Wang, Min, et al. "Decomposing the Apoptosis Pathway Into Biologically Interpretable Principal Components." Cancer informatics vol. 17 (2018): 1176935118771082. doi: https://doi.org/10.1177/1176935118771082
Wang M, Kornblau SM, Coombes KR. Decomposing the Apoptosis Pathway Into Biologically Interpretable Principal Components. Cancer Inform. 2018 May 09;17:1176935118771082. doi: 10.1177/1176935118771082. eCollection 2018. PMID: 29881252; PMCID: PMC5987987.
Copy Download .nbib Format: NLM
Hodgkin Lymphoma Cells Have a Specific Long Noncoding RNA Expression Pattern.

The American journal of pathology

Anfossi S, Calin GA.
PMID: 27456130
Am J Pathol. 2016 Sep;186(9):2251-3. doi: 10.1016/j.ajpath.2016.07.002. Epub 2016 Jul 25.

This commentary highlights the article by Tayari et al that suggests studying clinical implications of long noncoding RNAs as possible diagnostic and predictive biomarkers of Hodgkin lymphoma.

Cite
Anfossi S, Calin GA. Hodgkin Lymphoma Cells Have a Specific Long Noncoding RNA Expression Pattern. Am J Pathol. 2016;186(9):2251-3doi: 10.1016/j.ajpath.2016.07.002.
Anfossi, S., & Calin, G. A. (2016). Hodgkin Lymphoma Cells Have a Specific Long Noncoding RNA Expression Pattern. The American journal of pathology, 186(9), 2251-3. https://doi.org/10.1016/j.ajpath.2016.07.002
Anfossi, Simone, and Calin, George A. "Hodgkin Lymphoma Cells Have a Specific Long Noncoding RNA Expression Pattern." The American journal of pathology vol. 186,9 (2016): 2251-3. doi: https://doi.org/10.1016/j.ajpath.2016.07.002
Anfossi S, Calin GA. Hodgkin Lymphoma Cells Have a Specific Long Noncoding RNA Expression Pattern. Am J Pathol. 2016 Sep;186(9):2251-3. doi: 10.1016/j.ajpath.2016.07.002. Epub 2016 Jul 25. PMID: 27456130; PMCID: PMC5012504.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 17 entries